Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A transcription-based mechanism for oncogenic β-catenin-induced lethality in BRCA1/2-deficient cells

  • Dagg, Rebecca A.
  • Zonderland, Gijs
  • Puig Lombardi, Emilia
  • Rossetti, Giacomo G.
  • Groelly, Florian J.
  • Barroso, Sonia
  • Tacconi, Eliana M. C.
  • Wright, Benjamin
  • Lockstone, Helen
  • Aguilera, Andrés
  • Halazonetis, Thanos D.
  • Tarsounas, Madalena
BRCA1 or BRCA2 germline mutations predispose to breast, ovarian and other cancers. High-throughput sequencing of tumour genomes revealed that oncogene amplification and BRCA1/2 mutations are mutually exclusive in cancer, however the molecular mechanism underlying this incompatibility remains unknown. Here, we report that activation of β-catenin, an oncogene of the WNT signalling pathway, inhibits proliferation of BRCA1/2-deficient cells. RNA-seq analyses revealed β-catenin-induced discrete transcriptome alterations in BRCA2-deficient cells, including suppression of CDKN1A gene encoding the CDK inhibitor p21. This accelerates G1/S transition, triggering illegitimate origin firing and DNA damage. In addition, β-catenin activation accelerates replication fork progression in BRCA2-deficient cells, which is critically dependent on p21 downregulation. Importantly, we find that upregulated p21 expression is essential for the survival of BRCA2-deficient cells and tumours. Thus, our work demonstrates that β-catenin toxicity in cancer cells with compromised BRCA1/2 function is driven by transcriptional alterations that cause aberrant replication and inflict DNA damage., We are grateful to members of M.T. laboratory for critical reading of the manuscript and valuable feedback. Andrés Aguilera’s laboratory is funded by the European Research Council (grant ERC2014 AdG669898 TARLOOP). The work in Thanos Halazonetis’ laboratory was supported by grants from the Swiss National Science Foundation (182487) and the European Commission (ERC project REPLISTRESS). Research in Madalena Tarsounas’ laboratory is supported by Cancer Research UK and University of Oxford. This project has received funding from long-term EMBO non-stipendiary fellowship (ALTF 1044-2019), the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No. 722729 and grant agreement No. 886045. M.T. was the recipient of a Mayent-Rothschild-Institute Curie Award.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Small-molecule activation of OGG1 increases oxidative DNA damage repair by gaining a new function

  • Michel, Maurice
  • Benitez-Buelga, Carlos
  • Calvo, Patricia A.
  • Hanna, Bishoy M. F.
  • Mortusewicz, Oliver
  • Masuyer, Geoffrey
  • Davies, Jonathan
  • Wallner, Olov
  • Sanjiv, Kumar
  • Albers, Julian J.
  • Castañeda-Zegarra, Sergio
  • Jemth, Ann-Sofie
  • Visnes, Torkild
  • Sastre-Perona, Ana
  • Danda, Akhilesh N.
  • Homan, Evert J.
  • Marimuthu, Karthick
  • Zhenjun, Zhao
  • Chi, Celestine N.
  • Sarno, Antonio
  • Wiita, Elisée
  • Nicolai, Catharina von
  • Komor, Anna J.
  • Rajagopal, Varshni
  • Müller, Sarah
  • Hank, Emily C.
  • Varga, Marek
  • Scaletti, Emma R.
  • Pandey, Monica
  • Karsten, Stella
  • Haslene-Hox, Hanne
  • Loevenich, Simon
  • Marttila, Petra
  • Rasti, Azita
  • Mamonov, Kirill
  • Ortis, Florian
  • Schömberg, Fritz
  • Loseva, Olga
  • Stewart, Josephine
  • D’Arcy-Evans, Nicholas
  • Koolmeister, Tobias
  • Henriksson, Martin
  • Michel, Dana
  • Ory, Ana de
  • Acero, Lucia
  • Calvete, Oriol
  • Scobie, Martin
  • Hertweck, Christian
  • Vilotijevic, Ivan
  • Kalderén, Christina
  • Osorio, Ana
  • Perona Abellón, Rosario
  • Stolz, Alexandra
  • Stenmark, Pål
  • Warpman Berglund, Ulrika
  • Vega, Miguel de
  • Helleday, Thomas
Copyright © 2022 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. https://www.sciencemag.org/about/science-licenses-journal-article-reuse This is an article distributed under the terms of the Science Journals Default License., Oxidative DNA damage is recognized by 8-oxoguanine (8-oxoG) DNA glycosylase 1 (OGG1), which excises 8-oxoG, leaving a substrate for apurinic endonuclease 1 (APE1) and initiating repair. Here, we describe a small molecule (TH10785) that interacts with the phenylalanine-319 and glycine-42 amino acids of OGG1, increases the enzyme activity 10-fold, and generates a previously undescribed β,δ-lyase enzymatic function. TH10785 controls the catalytic activity mediated by a nitrogen base within its molecular structure. In cells, TH10785 increases OGG1 recruitment to and repair of oxidative DNA damage. This alters the repair process, which no longer requires APE1 but instead is dependent on polynucleotide kinase phosphatase (PNKP1) activity. The increased repair of oxidative DNA lesions with a small molecule may have therapeutic applications in various diseases and aging., This work was supported by European Research Council grant TAROX-695376 (T.H.); Swedish Research Council grant 2015-00162 (T.H.); Swedish Research Council grant 2018-03406 (P.S.); Ministry of Science and Innovation, Spain/State Research Agency, Spain/10.13039/501.100011033 and “ERDF A way to make Europe” grant BFU2017-83900-P (M.d.V.); Crafoord Foundation grant 20190532 (P.S.); an Alfred Österlund Foundation grant (P.S.); a Swedish Pain Relief Foundation grant (T.H.); Swedish Cancer Society grant CAN2018/0658 (T.H.); Swedish Cancer Society grant CAN 2017/716 (P.S.); a Torsten and Ragnar Söderberg foundation grant (T.H.); Dr. Åke-Olsson Foundation for Hematological Research grant 2020-00306 (M.M.); the Thomas Helleday Foundation for medical research postdoctoral stipends (M.M. and C.B.-B.); the NTNU Enabling Technology Programme on Biotechnology to Valentyn Oksenych (S.C.-Z.); EMBO Short-Term Fellowship 9005 (S.C.-Z.); a FEBS Short-Term Fellowship (S.C.-Z.); SSI Grants for Scandinavian Exchange (S.C.-Z.); German Research Foundation (DFG) 239748522 (A.J.K. and C.H.); Sonderforschungsbereich (SFB) 1127 (A.J.K. and C.H.); The Leibniz Award (C.H.); Norwegian Research Council grant 303369 (T.V.); Karolinska Institutet Research Foundation grant 2020-02186 (M.M.); a Lars Hiertas Minne Stiftelse grant (M.M.); and Asociacion Española Contra Cancer grant Postdoctoral AECC 2020, Nº POSTD20042BENI (C.B.-B.). This study was funded by “Instituto de Salud Carlos III CP19/00063 and PI20/00329” and cofunded by European Social Fund “Investigating in your future” and “European Regional Development Fund” (A.S.-P.). CNIO studies are partially funded by Instituto de Salud Carlos III, project reference PI19/00640, and cofounded by the European Regional Development Fund (ERDF), “A way to make Europe” (A.O.). This project received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement no. 875510 (M.M., E.J.H., E.W., and A.St.). This work received funding from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement no. 722729 (T.H. and B.M.F.H.)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Cellular Senescence: Defining a Path Forward

  • Gorgoulis, Vassilis
  • Adams, Peter D.
  • Alimonti, Andrea
  • Bennett, Dorothy C.
  • Bischof, Oliver
  • Bishop, Cleo
  • Campisi, Judith
  • Collado, Manuel
  • Evangelou, Konstantinos
  • Ferbeyre, Gerardo
  • Gil, Jesús
  • Hara, Eiji
  • Krizhanovsky, Valery
  • Jurk, Diana
  • Maier, Andrea B.
  • Narita, Masashi
  • Niedernhofer, Laura J.
  • Passos, João F.
  • Robbins, Paul D.
  • Schmitt, Clemens A.
  • Sedivy, John
  • Vougas, Konstantinos
  • Zglinicki, Thomas von
  • Zhou, Daohong
  • Serrano, Manuel
  • Demaria, Marco
Cellular senescence is a cell state implicated in various physiological processes and a wide spectrum of age-related diseases. Recently, interest in therapeutically targeting senescence to improve healthy aging and age-related disease, otherwise known as senotherapy, has been growing rapidly. Thus, the accurate detection of senescent cells, especially in vivo, is essential. Here, we present a consensus from the International Cell Senescence Association (ICSA), defining and discussing key cellular and molecular features of senescence and offering recommendations on how to use them as biomarkers. We also present a resource tool to facilitate the identification of genes linked with senescence, SeneQuest (available at http://Senequest.net). Lastly, we propose an algorithm to accurately assess and quantify senescence, both in cultured cells and in vivo., M.D. is funded by the Dutch Cancer Foundation, Netherlands (grant ID 10989). V.G., K.E., and K.V. were financially supported by the European Union’s Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grants agreement no. 722729 (SYNTRAIN); the Welfare Foundation for Social & Cultural Sciences (KIKPE), Greece; the KIKPE Foundation, Athens, Greece; Pentagon Biotechnology, UK; DeepMed IO, UK; grant no. 775 from the Hellenic Foundation for Research and Innovation (HFRI); and NKUA-SARG grants 70/3/9816, 70/3/12128, and 70/3/15603. M.S.: is funded by the IRB and by grants from the Spanish Ministry of Economy co-funded by the European Regional Development Fund (ERDF) (SAF2013-48256-R), the European Research Council (ERC-2014-AdG/669622), and “laCaixa” Foundation., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Chlorambucil targets BRCA1/2‐deficient tumours and counteracts PARP inhibitor resistance

  • Tacconi, Eliana M. C.
  • Badie, Sophie
  • Gregoriis, Giuliana De
  • Reisländer, Timo
  • Lai, Xianning
  • Porru, Manuela
  • Folio, Cecilia
  • Moore, John
  • Kopp, Arnaud
  • Baguña Torres, Júlia
  • Sneddon, Deborah
  • Green, Marcus
  • Dedic, Simon
  • Lee, Jonathan W.
  • Sati Batra, Ankita
  • Rueda, Oscar M.
  • Bruna, Alejandra
  • Leonetti, Carlo
  • Caldas, Carlos
  • Cornelissen, Bart
  • Brino, Laurent
  • Ryan, Anderson
  • Biroccio, Annamaria
  • Tarsounas, Madalena
Due to compromised homologous recombination (HR) repair, BRCA1‐ and BRCA2‐mutated tumours accumulate DNA damage and genomic rearrangements conducive of tumour progression. To identify drugs that target specifically BRCA2‐deficient cells, we screened a chemical library containing compounds in clinical use. The top hit was chlorambucil, a bifunctional alkylating agent used for the treatment of chronic lymphocytic leukaemia (CLL). We establish that chlorambucil is specifically toxic to BRCA1/2‐deficient cells, including olaparib‐resistant and cisplatin‐resistant ones, suggesting the potential clinical use of chlorambucil against disease which has become resistant to these drugs. Additionally, chlorambucil eradicates BRCA2‐deficient xenografts and inhibits growth of olaparib‐resistant patient‐derived tumour xenografts (PDTXs). We demonstrate that chlorambucil inflicts replication‐associated DNA double‐strand breaks (DSBs), similarly to cisplatin, and we identify ATR, FANCD2 and the SNM1A nuclease as determinants of sensitivity to both drugs. Importantly, chlorambucil is substantially less toxic to normal cells and tissues in vitro and in vivo relative to cisplatin. Because chlorambucil and cisplatin are equally effective inhibitors of BRCA2‐compromised tumours, our results indicate that chlorambucil has a higher therapeutic index than cisplatin in targeting BRCA‐deficient tumours., The work in A.B. laboratory was supported by Ministry of Health (Ricerca Corrente 2018) and Italian Association for Cancer Research (IG AIRC grant 21579). This project has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska‐Curie grant agreement No. 722729. Research in M.T. laboratory is supported by Cancer Research UK, Medical Research Council and University of Oxford., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

FANCD2 restrains fork progression and prevents fragility at early origins upon re-replication

  • Badra-Fajardo, Nibal
  • Karydi, Elena
  • Bayona-Feliu, Aleix
  • Gómez-González, Belén
  • Preza, Ourania
  • Arbi, Marina
  • Kalogeropoulou, Argyro
  • Rantala, Juha K.
  • Taraviras, Stavros
  • Aguilera, Andrés
  • Lygerou, Zoi
DNA replication is tightly regulated to ensure a single round of chromosome duplication per cell division. DNA licensing restricts origin firing to once-per-cell-cycle while aberrant licensing promotes re-replication and genome instability. Here, we investigate the mechanisms that protect genome integrity following re-replication induced by depletion of the licensing inhibitor Geminin. We find that re-replicating cells require FANCD2 to prevent genome instability. FANCD2 is rapidly recruited to chromatin upon Geminin loss, where it limits unrestrained fork progression and prevents single strand DNA gap accumulation and fork breakage. Genome-wide analyses reveal that upon re-replication, FANCD2 localizes to early origins within highly transcribed regions prone to accumulate R-loops and enriched in early replicating fragile sites. Importantly, reducing transcription and R-loops alleviates re-replication-induced genome fragility, whereas PARP inhibition exacerbates it. Our study uncovers a role for FANCD2 in safeguarding genome integrity during re-replication, offering avenues for selective targeting of cancer cells., We thank the Advanced Light Microscopy facility at the Medical School of the University of Patras for their support with experiments and the members of our groups for insightful discussions. We are also grateful to Dr. Raphael Ceccaldi for sharing the PD20 cells, Dr. Bert van de Kooij for sharing the FANCD2-KO and corrected U2OS cells and Dr. Vassilis Roukos for scientific advice in the generation of the mAID-Geminin HCT116 cells. This study was supported by research funding from the European Union Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement No. 722729, the European Union Horizon Europe (2021-2027), “ESPERANCE” ERA Chair program (GA 101087215), the Hellenic Foundation for Research and Innovation (H.F.R.I.) under the “2nd Call for H.F.R.I. Research Projects to support Faculty Members & Researchers” (Project Number: 2728) and the project TAEDR-0539180 implemented within the framework of “Actions in interdisciplinary scientific areas with special interests for the connection with the productive fabric”, Greece 2.0 - National Recovery and Resilience Plan to Z.L. N.B.F. received fellowships from the Federation of European Biochemical Societies (FEBS) and the Operational Programme «Human Resources Development, Education and Lifelong Learning 2014- 2020» (IKY). This work was also funded by grants from the Spanish Agencia Estatal de Investigación (PID2022-138251NB-I00 funded by MCIN/AEI/10.13039/501100011033 “ERDF A way of making Europe”) and the Caixa Research Foundation (LCF/PR/HR22/52420014) to A.A. The publication fees of this manuscript have been financed by the Research Council of the University of Patras., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Small molecule inhibitor of OGG1 blocks oxidative DNA damage repair at telomeres and potentiates methotrexate anticancer effects

  • Baquero, Juan Miguel|||0000-0002-6488-7742
  • Benítez-Buelga, Carlos
  • Rajagopal, Varshni
  • Zhenjun, Zhao
  • Torres, Raul|||0000-0001-9606-0398
  • Müller, Sarah
  • Hanna, Bishoy M. F.|||0000-0001-7027-6553
  • Loseva, Olga
  • Wallner, Olov|||0000-0002-6481-237X
  • Michel, Maurice|||0000-0003-3261-2493
  • Rodriguez-Perales, Sandra|||0000-0001-7221-3636
  • Gad, Helge|||0000-0001-6530-1443
  • Visnes, Torkild|||0000-0003-1047-988X
  • Helleday, Thomas|||0000-0002-7384-092X
  • Benitez, Javier|||0000-0002-0923-7202
  • Osorio, Ana|||0000-0001-8124-3984
The most common oxidative DNA lesion is 8-oxoguanine which is mainly recognized and excised by the 8-oxoG DNA glycosylase 1 (OGG1), initiating the base excision repair (BER) pathway. Telomeres are particularly sensitive to oxidative stress (OS) which disrupts telomere homeostasis triggering genome instability. In the present study, we have investigated the effects of inactivating BER in OS conditions, by using a specific inhibitor of OGG1 (TH5487). We have found that in OS conditions, TH5487 blocks BER initiation at telomeres causing an accumulation of oxidized bases, that is correlated with telomere losses, micronuclei formation and mild proliferation defects. Moreover, the antimetabolite methotrexate synergizes with TH5487 through induction of intracellular reactive oxygen species (ROS) formation, which potentiates TH5487-mediated telomere and genome instability. Our findings demonstrate that OGG1 is required to protect telomeres from OS and present OGG1 inhibitors as a tool to induce oxidative DNA damage at telomeres, with the potential for developing new combination therapies for cancer treatment.